artificial intelligence
-
Which way for EU data governance during COVID-19?
Since the unprecedented outbreak of the COVID-19 virus, the use of data has extensively been discussed. What obstacles do scientists, public health officials and private companies face when processing datasets? And how much digital privacy can EU citizens afford in times of crisis?
-
A scientist’s opinion : Interview with Prof. Anna Odone about COVID-19 & GDPR
We speak with Anna Odone, Associate Professor of Public Health at the Faculty of Medicine of the University Vita-Salute San Raffaele in Milan. As a consultant physician, responsible for the Unit of Clinical Epidemiology and Health Technology Assessment at San Raffaele Scientific Institute, she is the... -
A scientist’s opinion : Interview with Henry Ajder about Deepfakes
The key point I would make about regulating deepfakes is that, in some cases, new laws may be needed, but much of the harm deepfakes cause is covered by existing laws, or could be covered by amending existing laws.
-
A scientist’s opinion : Interview with Denis Teyssou about Deepfakes
Synthetic audio means that it will be possible to make any person say anything, making it even easier to make politicians or celebrities victims of deepfake as there is a lot of publicly accessible audio of their voices.
-
A scientist’s opinion : Interview with Sam Gregory about Deepfakes
Rhetoric about the ‘end of truth’ plays into the hands of people who already are saying you can’t believe anything – and that is neither true of most audiovisual material, nor true yet for deepfakes. We should not panic but prepare instead.
-
EU Project : PhilHumans
PhilHumans : The goal of the PhilHumans (Personal Health Interfaces Leveraging Human-MAchine Natural interactionS) project is to train a next generation of young researchers in innovative Artificial Intelligence (AI) and establish user interaction with their personal health devices in an advanced and... -
EU Project : CLARIFY
CLARIFY : There were 17 million new cases of cancer diagnosed worldwide in 2018. Survival rates of cancer patients were rather poor until recent decades, when diagnostic techniques have been improved and novel therapeutic options have been developed. It is estimated that more than 50% of adult patients... -
EU Project : PATH-TOX
PATH-TOX: Drug discovery is a time consuming, expensive and risky process. Each drug to market must undergo safety/ toxicity testing in animals which yields thousands of tissue sections that currently must be assessed manually by a trained veterinary pathology. However, there is a looming crisis due...